GlassScriptPhysician profile
Pritesh R Patel
NPI 1396966941
$118,331.52
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $24K · 2021: $719 · 2022: $410 · 2023: $4,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,148.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $58,571.88 | 2019-2020 | |
| Amgen INC. | $46,399.56 | 2019-2020 | |
| Janssen Biotech, INC. | $7,538.50 | 2019-2022 | |
| Ge Healthcare | $4,148.00 | 2023 | |
| Genzyme Corporation | $719.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $330.48 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $225.46 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $120.47 | 2019 | |
| Seagen INC. | $105.31 | 2019 | |
| Covidien LP | $89.94 | 2019 | |
| Verastem, INC. | $82.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pritesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.